AbCellera announces collaboration with Vertex to develop T-cell engagers; receives $281M upfront

AbCellera Biologics Inc.

Collaboration with Vertex (VRTX) to discover multispecific T-cell engagers for autoimmune diseases and other conditions.
AbCellera leads discovery and early development; Vertex funds all R&D costs and holds commercialization rights.
AbCellera receives $281 million in total upfront payments, plus preclinical, development, regulatory, and commercial milestones and tiered royalties.
AbCellera may also perform cell line development, process development, and clinical manufacturing through Phase 1 for any program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.